+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe Inhalation and Nasal Spray Generic Drugs Market Size, Share & Industry Trends Analysis Report By End-user, By Indication, By Distribution Channel, By Demographics, By Country and Growth Forecast, 2022 - 2028

  • PDF Icon

    Report

  • 111 Pages
  • August 2022
  • Region: Europe
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5659241
The Europe Inhalation and Nasal Spray Generic Drugs Market is expected to witness market growth of 8.1% CAGR during the forecast period (2022-2028).

Some nasal sprays, including steroid and antihistamine sprays, are intended specifically to relieve allergy symptoms and can also be applied repeatedly. Decongestant nasal sprays, a third kind, are best for relieving congestion caused by the flu or a cold because they should only be utilized for a few days at a time.

Drugs can be administered locally within nasal cavities or systemically through nasal sprays. They are applied locally to treat problems, like allergic rhinitis and nasal congestion. Because it offers a comfortable alternative to injection or tablet, the nasal administration route is occasionally chosen for systemic therapy.

Through the nose, substances can be directly and quickly absorbed. Numerous pharmaceuticals are available as nasal sprays for systemic use (e.g. treatments for migraine, sedative-analgesics, osteoporosis, and nausea). Hormone replacement therapy, Parkinson's and Alzheimer's disease treatment, and other uses are also possible. Nasal sprays are considered to be a more effective drug delivery method with the potential to pass the blood-brain barrier.

The use of tobacco is substantially high in the regional countries. With an estimated 209 million people (or 29%) smoking, the WHO European Region has the highest rate of tobacco use in the world. Additionally, 74 million women also smoke in Europe, and the Region has the maximum smoking prevalence among them. The region-wide prevalence of tobacco consumption varies greatly. The use of tobacco contributes significantly to health disparities and is the main cause of mortality and disability in the region.

The Germany market is leading the Europe Inhalation and Nasal Spray Generic Drugs Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $1,998.9 million by 2028. The UK market is expected to showcase a CAGR of 7.2% during (2022 - 2028). Additionally, The France market is experiencing a CAGR of 8.9% during (2022 - 2028).

Based on End-user, the market is segmented into Homecare, Hospitals, and Others. Based on Drugs Class, the market is segmented into Bronchodilators, Combination Drugs, Antihistamines, Corticosteroids, Decongestant Sprays, and Others. Based on Indication, the market is segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, and Others. Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospitals Pharmacy, and Online Pharmacies. Based on Demographics, the market is segmented into Adult Patient, Geriatric Patient, and Pediatric Patient. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris, Inc., Akorn, Operating Company LLC, Cipla Limited, Teva Pharmaceuticals Industries Ltd., Novartis AG (Sandoz International GmBH), Apotex, Inc., Hikma Pharmaceuticals PLC, Sun Pharmaceuticals Industries Ltd., Beximco Pharmaceuticals Ltd.

Scope of the Study

Market Segments Covered in the Report:

By End-user
  • Homecare
  • Hospitals
  • Others
By Drugs Class
  • Bronchodilators
  • Combination Drugs
  • Antihistamines
  • Corticosteroids
  • Decongestant Sprays
  • Others
By Indication
  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Allergic Rhinitis
  • Others
By Distribution Channel
  • Retail Pharmacy
  • Hospitals Pharmacy
  • Online Pharmacies
By Demographics
  • Adult Patient
  • Geriatric Patient
  • Pediatric Patient
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

  • Viatris, Inc.
  • Akorn, Operating Company LLC
  • Cipla Limited
  • Teva Pharmaceuticals Industries Ltd.
  • Novartis AG (Sandoz International GmBH)
  • Apotex, Inc.
  • Hikma Pharmaceuticals PLC
  • Sun Pharmaceuticals Industries Ltd.
  • Beximco Pharmaceuticals Ltd.

Unique Offerings from the Publisher

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Inhalation And Nasal Spray Generic Drugs Market, by End-user
1.4.2 Europe Inhalation And Nasal Spray Generic Drugs Market, by Drugs Class
1.4.3 Europe Inhalation And Nasal Spray Generic Drugs Market, by Indication
1.4.4 Europe Inhalation And Nasal Spray Generic Drugs Market, by Distribution Channel
1.4.5 Europe Inhalation And Nasal Spray Generic Drugs Market, by Demographics
1.4.6 Europe Inhalation And Nasal Spray Generic Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Inhalation And Nasal Spray Generic Drugs Market by End-user
3.1 Europe Homecare Market by Country
3.2 Europe Hospitals Market by Country
3.3 Europe Others Market by Country
Chapter 4. Europe Inhalation And Nasal Spray Generic Drugs Market by Drugs Class
4.1 Europe Bronchodilators Market by Country
4.2 Europe Combination Drugs Market by Country
4.3 Europe Antihistamines Market by Country
4.4 Europe Corticosteroids Market by Country
4.5 Europe Decongestant Sprays Market by Country
4.6 Europe Others Market by Country
Chapter 5. Europe Inhalation And Nasal Spray Generic Drugs Market by Indication
5.1 Europe Asthma Market by Country
5.2 Europe Chronic Obstructive Pulmonary Disease (COPD) Market by Country
5.3 Europe Allergic Rhinitis Market by Country
5.4 Europe Others Market by Country
Chapter 6. Europe Inhalation And Nasal Spray Generic Drugs Market by Distribution Channel
6.1 Europe Retail Pharmacy Market by Country
6.2 Europe Hospitals Pharmacy Market by Country
6.3 Europe Online Pharmacies Market by Country
Chapter 7. Europe Inhalation And Nasal Spray Generic Drugs Market by Demographics
7.1 Europe Adult Patient Market by Country
7.2 Europe Geriatric Patient Market by Country
7.3 Europe Pediatric Patient Market by Country
Chapter 8. Europe Inhalation And Nasal Spray Generic Drugs Market by Country
8.1 Germany Inhalation And Nasal Spray Generic Drugs Market
8.1.1 Germany Inhalation And Nasal Spray Generic Drugs Market by End-user
8.1.2 Germany Inhalation And Nasal Spray Generic Drugs Market by Drugs Class
8.1.3 Germany Inhalation And Nasal Spray Generic Drugs Market by Indication
8.1.4 Germany Inhalation And Nasal Spray Generic Drugs Market by Distribution Channel
8.1.5 Germany Inhalation And Nasal Spray Generic Drugs Market by Demographics
8.2 UK Inhalation And Nasal Spray Generic Drugs Market
8.2.1 UK Inhalation And Nasal Spray Generic Drugs Market by End-user
8.2.2 UK Inhalation And Nasal Spray Generic Drugs Market by Drugs Class
8.2.3 UK Inhalation And Nasal Spray Generic Drugs Market by Indication
8.2.4 UK Inhalation And Nasal Spray Generic Drugs Market by Distribution Channel
8.2.5 UK Inhalation And Nasal Spray Generic Drugs Market by Demographics
8.3 France Inhalation And Nasal Spray Generic Drugs Market
8.3.1 France Inhalation And Nasal Spray Generic Drugs Market by End-user
8.3.2 France Inhalation And Nasal Spray Generic Drugs Market by Drugs Class
8.3.3 France Inhalation And Nasal Spray Generic Drugs Market by Indication
8.3.4 France Inhalation And Nasal Spray Generic Drugs Market by Distribution Channel
8.3.5 France Inhalation And Nasal Spray Generic Drugs Market by Demographics
8.4 Russia Inhalation And Nasal Spray Generic Drugs Market
8.4.1 Russia Inhalation And Nasal Spray Generic Drugs Market by End-user
8.4.2 Russia Inhalation And Nasal Spray Generic Drugs Market by Drugs Class
8.4.3 Russia Inhalation And Nasal Spray Generic Drugs Market by Indication
8.4.4 Russia Inhalation And Nasal Spray Generic Drugs Market by Distribution Channel
8.4.5 Russia Inhalation And Nasal Spray Generic Drugs Market by Demographics
8.5 Spain Inhalation And Nasal Spray Generic Drugs Market
8.5.1 Spain Inhalation And Nasal Spray Generic Drugs Market by End-user
8.5.2 Spain Inhalation And Nasal Spray Generic Drugs Market by Drugs Class
8.5.3 Spain Inhalation And Nasal Spray Generic Drugs Market by Indication
8.5.4 Spain Inhalation And Nasal Spray Generic Drugs Market by Distribution Channel
8.5.5 Spain Inhalation And Nasal Spray Generic Drugs Market by Demographics
8.6 Italy Inhalation And Nasal Spray Generic Drugs Market
8.6.1 Italy Inhalation And Nasal Spray Generic Drugs Market by End-user
8.6.2 Italy Inhalation And Nasal Spray Generic Drugs Market by Drugs Class
8.6.3 Italy Inhalation And Nasal Spray Generic Drugs Market by Indication
8.6.4 Italy Inhalation And Nasal Spray Generic Drugs Market by Distribution Channel
8.6.5 Italy Inhalation And Nasal Spray Generic Drugs Market by Demographics
8.7 Rest of Europe Inhalation And Nasal Spray Generic Drugs Market
8.7.1 Rest of Europe Inhalation And Nasal Spray Generic Drugs Market by End-user
8.7.2 Rest of Europe Inhalation And Nasal Spray Generic Drugs Market by Drugs Class
8.7.3 Rest of Europe Inhalation And Nasal Spray Generic Drugs Market by Indication
8.7.4 Rest of Europe Inhalation And Nasal Spray Generic Drugs Market by Distribution Channel
8.7.5 Rest of Europe Inhalation And Nasal Spray Generic Drugs Market by Demographics
Chapter 9. Company Profiles
9.1 Viatris, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.2 Akorn Operating Company LLC
9.2.1 Company Overview
9.3 Cipla Limited
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expense
9.4 Teva Pharmaceutical Industries Ltd.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Regional Analysis
9.4.4 Research & Development Expenses
9.4.5 Recent strategies and developments:
9.4.5.1 Product Launches and Product Expansions:
9.5 Novartis AG (Sandoz International GmbH)
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.6 Apotex, Inc.
9.6.1 Company Overview
9.7 Hikma Pharmaceuticals PLC
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expenses
9.7.5 Recent strategies and developments:
9.7.5.1 Product Launches and Product Expansions:
9.8 Sun Pharmaceuticals Industries Ltd.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Research & Development Expenses
9.9 Beximco Pharmaceuticals Ltd.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses

Companies Mentioned

  • Viatris, Inc.
  • Akorn, Operating Company LLC
  • Cipla Limited
  • Teva Pharmaceuticals Industries Ltd.
  • Novartis AG (Sandoz International GmBH)
  • Apotex, Inc.
  • Hikma Pharmaceuticals PLC
  • Sun Pharmaceuticals Industries Ltd.
  • Beximco Pharmaceuticals Ltd.

Methodology

Loading
LOADING...